Concert Pharmaceuticals, Inc. (CNCE)’s director Richard Aldrich Unloaded 30,000 Shares of the Company; Seadrill Limited (SDRL) Shorts Up By 5.83%

Because of the transaction Richard Aldrich made he is in the traders attention today. The director of Concert Pharmaceuticals Inc and an insider, sold 30,000 shares worth $580,400 US Dollars. The average price was $19.3 per share. In the last month, he also sold 31,236 shares worth total $597,833 USD. This transaction was conducted on November 19, 2018. A report submitted with the SEC and free at your disposal here, reveals more info for the transaction. he presently holds 1.72% of the stock market capitalization of Concert Pharmaceuticals Inc.

Seadrill Limited (NYSE:SDRL) had an increase of 5.83% in short interest. SDRL’s SI was 26.21M shares in January as released by FINRA. Its up 5.83% from 24.76 million shares previously. With 3.72M avg volume, 7 days are for Seadrill Limited (NYSE:SDRL)’s short sellers to cover SDRL’s short positions. The SI to Seadrill Limited’s float is 7.48%. The stock 0.67% or $0 during the last trading session, reaching $0.28. It is down 83.13% since January 19, 2017 and is downtrending. It has underperformed by 99.83% the S&P500.

Seadrill Limited, an offshore drilling contractor, provides offshore drilling services to the gas and oil industry worldwide. The company has market cap of $141.24 million. The firm operates through three divisions: Floaters, Jack-up Rigs, and Other. It currently has negative earnings. The Floaters segment provides drilling, completion, and maintenance services for offshore exploration and production wells.

Among 10 analysts covering Seadrill (NYSE:SDRL), 2 have Buy rating, 3 Sell and 5 Hold. Therefore 20% are positive. Seadrill had 21 analyst reports since August 20, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Credit Suisse given on Thursday, September 3. Morgan Stanley downgraded SeaDrill Limited (NYSE:SDRL) on Thursday, January 28 to “Equal-Weight” rating. Morgan Stanley downgraded the shares of SDRL in report on Tuesday, July 26 to “Equal-Weight” rating. The firm has “Underweight” rating by JP Morgan given on Monday, January 18. The stock of SeaDrill Limited (NYSE:SDRL) earned “Strong-Buy” rating by Vetr on Friday, August 28. The stock has “Perform” rating by Oppenheimer on Monday, November 30. The stock of SeaDrill Limited (NYSE:SDRL) has “Sector Perform” rating given on Tuesday, September 1 by Scotia Capital. The rating was maintained by Canaccord Genuity with “Sell” on Wednesday, September 2. The firm has “Neutral” rating by Seaport Global Securities given on Friday, December 18. The rating was downgraded by Vetr on Wednesday, September 2 to “Buy”.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Concert Pharmaceuticals has $34.0 highest and $20.0 lowest target. $27’s average target is 37.68% above currents $19.61 stock price. Concert Pharmaceuticals had 22 analyst reports since August 12, 2015 according to SRatingsIntel. H.C. Wainwright maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rating on Friday, November 10. H.C. Wainwright has “Buy” rating and $21.0 target. On Wednesday, August 12 the stock rating was initiated by Brean Capital with “Buy”. As per Thursday, October 19, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Aegis Capital with “Buy” on Thursday, June 29. The stock has “Buy” rating by H.C. Wainwright on Monday, September 18. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. H.C. Wainwright maintained the stock with “Buy” rating in Friday, October 20 report. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 1. As per Wednesday, September 9, the company rating was initiated by Aegis Capital.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on March, 5. They expect $-0.18 earnings per share, up 66.67% or $0.36 from last year’s $-0.54 per share. After $-0.70 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -74.29% EPS growth.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $446.57 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.05 P/E ratio. The company??s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer??s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Since September 14, 2017, it had 1 insider purchase, and 2 insider sales for $4.61 million activity. On Thursday, September 14 the insider Lynch Ryan sold $50,785. ALDRICH RICHARD also sold $597,833 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares. BVF PARTNERS L P/IL also bought $5.26 million worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Thursday, October 19.

The stock decreased 0.51% or $0.1 during the last trading session, reaching $19.61. About 505,075 shares traded or 7.48% up from the average. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 18.70% since January 19, 2017 and is uptrending. It has outperformed by 2.00% the S&P500.